The purpose of the study was to examine the levels of transforming growth factor-β1 in the serum of patients with coronary heart disease in combination with type 2 diabetes and without it. Material and methods. We conducted a survey of 65 patients (25 men, 40 women) aged from 36 to 69 years (mean age was (59±3.5) years). All patients were diagnosed with coronary heart disease in the form of stable angina pectoris I-II functional classes. The group of examined patients included 33 patients with concomitant type 2 diabetes mellitus (mild form was in 15 people; moderate was in 18 people) and 32 patients without diabetes mellitus. The scope of the survey covered the generally accepted methods of clinical, laboratory and instrumental examination. The group of patients with coronary heart disease with type 2 diabetes had 14 (43%) men and 19 (57%) women (mean age was (62±2.6) years. Heart failure of stage I-II A (I-II functional classes) was diagnosed in 22 (68%) patients. The duration of coronary heart disease was from 3 to 15 years, the duration of type 2 diabetes lasted from 3 to 14. We detected hypertension in 19 (57%) patients, it was within 1-2 degrees (according to the criteria of the Ukrainian Association of Cardiologists, 2008). In the group of patients with coronary heart disease without diabetes there were 11 men (34%), 21 women (66%) (mean age was (57.0±2.4) years). Hypertension within 1-2 degrees was detected in 15 (46%) patients. Heart failure of I-II A stages (I-II functional classes) was diagnosed in 15 (46%) patients. The control group consisted of 15 practically healthy individuals who were representative by sex and age of patients from the study group and who did not have diseases of the cardiovascular system and endocrinopathies. The level of transforming growth factor-β1 in the blood serum was determined using sets of standard test systems "TGF-β1 ELISA" produced by company "DRG Instruments" (Germany). The level of native transforming growth factor-β1 in the serum was determined by solid-phase enzyme-linked immunosorbent assay. Results and discussion. Groups of patients with coronary heart disease with type 2 diabetes and without it could be compared by age, sex, duration and severity of coronary heart disease, the frequency of concomitant hypertension. At the same time, among patients with coronary heart disease with type 2 diabetes there was a higher frequency of heart failure. The results showed that probable increase in serum transforming growth factor-β1 levels in patients with coronary heart disease was more pronounced when combining coronary heart disease with type 2 diabetes. There was a significant increase in serum of transforming growth factor -β1 levels in patients with coronary heart disease both with type 2 diabetes and without it with a longer course of coronary heart disease and were severer, in patients with coronary heart disease with type 2 diabetes was with a longer course of diabetes. Analysis of the nature of changes in the levels of transforming growth factor-β1 in the serum of the examined patients with coronary heart disease with type 2 diabetes and without it, depending on gender, did not reveal any significant differences. The results of the study also indicated that in patients with coronary heart disease with type 2 diabetes and without it for all duration of coronary heart disease, the levels of this indicator in the serum were probably (p <0.05) higher than those in the control group. However, in patients with a significant duration of coronary heart disease (5-10 years and over 10 years) serum levels of transforming growth factor-β1 were probably (p <0.05) higher than in patients with a duration of coronary heart disease less than 5 years, and in the presence of and in the absence of type 2 diabetes. At the same time, for all periods of coronary heart disease, the levels of transforming growth factor-β1 in patients with type 2 diabetes were probably higher than in patients without diabetes. Conclusion. A probable increase in the levels of transforming growth factor -β1 in the serum of patients with coronary heart disease, which was more pronounced when combining coronary heart disease with type 2 diabetes. There was a significant increase in the levels of transforming growth factor-β1 in the serum of patients with coronary heart disease both with type 2 diabetes and without it with a longer course of coronary heart disease and its severe degree, in patients with coronary heart disease with type 2 diabetes especially with a longer course of diabetes. In order to increase the informativeness of assessing the risk of cardiovascular complications and the nature of coronary heart disease in patients with type 2 diabetes, the survey should include determination of serum levels of potent profibrogenic factor like transforming growth factor-β1

Aim. To assess the level of cognitive impairment and its dynamics over 6 months in Parkinson’s disease. Materials and methods. The study involved 31 people with Parkinson’s disease, including 15 women and 16 men. The average age of patients at the beginning of the study was 65.1 (m = 0.54). The duration of the disease varied from 3 to 8 years. The Mini-mental State Examination (MMSE) and the Mattis dementia scale were used to study cognitive functions. The Wechsler Adult Intelligence Scale (WAIS) was used to assess attention. The study of speech was conducted using the free and directed association test, and visual-spatial functions were studied using the “drawing clock” test. The visual memory test from the SKT test battery was used to assess memory, and affective disorders were studied using the Beck Depression Scale. Depression was diagnosed according to the ICD-10 criteria. The vegetative disorders were assessed using the autonomic disorders scale. The results obtained were processed using mathematical statistics methods. Results. The data obtained in the course of the study allow us to state the stability in disturbance of the vegetative function. The affective symptoms in patients with mild cognitive impairment were improved. In patients with moderate and severe cognitive impairment, affective symptoms remained stable. There were also no significant changes in the Mattis dementia scale, the Beck Depression Scale, the coding test, visual-spatial functions, grammatical associations, semantics and phonetics. Conclusions. The studies showed that after the introduction of a comprehensive rehabilitation program for 6 months there were minor improvements indicating the need for further improvement and implementation.

No abstract

Визначення гострої токсичності лікарської форми «Латирон»Актуальність. Лікарські рослини здавна привертають увагу дослідників як носії біологічно активних ре-човин, що зумовлює їх цілющі властивості. Пошук та створення лікарських препаратів рослинного походжен-ня -одна з найважливіших задач фармацевтичної науки. За даними народної медицини чина посівна має різні властивості, одна з яких -протиаритмічна. Результати попередніх досліджень, проведених на кафедрі фізіології НФаУ, довели перспективність використання комплексу біологічно активних речовин з чини посівної.Метою даного дослідження стало експериментальне вивчення гострої токсичності лікарської форми «Латирон». Матеріали та методи. Гостру токсичність латирону вивчали на двох видах тварин: мишах і щурах при двох шляхах уведення: внутрішньошлунковому і внутрішньоочеревинному. Сполуки вводили у вигляді водних розчинів.Результати та їх обговорення. Аналіз результатів свідчить про те, що середньосмертельна доза латирону при внутрішньоочеревинному введенні для мишей становить 3740 мг/кг, а для шурів -2310 мг/кг; внутрішньошлун-кове введення латирону мишам у дозах від 4000 до 6000 мг/кг, а щурам від 6000 до 11000 мг/кг маси тіла дозво-лило встановити, що LD 50 , для мишей складає 4870 мг/кг, для щурів -1948 мг/кг. Спостереження за тваринами вели впродовж 3-х діб. При порівнянні гострої токсичності латирону з препаратами порівняння встановили, що латирон у 3,8 рази менш токсичний за аймалін і в 4,6 рази -за алапінін.Висновки. Узагальнюючи отримані результати, можна зробити висновок, що латирон за класифікацією Сидорова К. К. відноситься до практично нетоксичних речовин, а в порівнянні з препаратами порівняння у 3,8 рази менш токсичний за аймалін і в 4,6 рази -за алапінін. Acute toxicity determination of "Latiron" medicinal form Topicality. Medical plants since olden times attracted attention for researchers by curative properties of its bioactive substances. Searching and creation of medicinal preparations of plant origin is one of the major tasks of pharmaceutical science. From data of folk medicine чина sowing is different characteristics, and one of them -anti-arrhythmic. By the previous researches conducted on the department of physiology of NUPH perspective of the use of medicinal form "Latiron" was well-proven.Aim. The aim of this research was experimental study of acute toxicity of the medicinal form "Latiron" in tablets. Materials and methods. The acute toxicity of the medicinal form "Latiron" in tablets had been studied in experimental on two types of laboratory animal: mice and rats at two ways of introduction: intragastric and intraperitoneal. Connections entered as water solutions.Results and discussion. The analysis of results testifies that the medium-lethal dose of preparation at intraperitoneal introduction for mice makes 3740 mg/kg, and for rats 2310 mg/kg, intragastric introduction to "Latiron" mice in doses a from 4000 to 6000 mg/kg, a from 6000 to 11000 mg/kg of body weight allowed rats to set that LD 50 , for mice makes 4870 mg/kg, for rats 194...

The purpose of this research is to compare and determine the level of health of first-year female students of NUPh in the 2018-2021 academic years. Material & Methods: the research involved 528 first-year female students of National University of Pharmacy (the year of entry 2018 (n=311); the year of entry 2019 (n=107); the year of entry 2020 (n=60); the year of entry 2021 (n=50)). Anthropometric parameters (body weight, standing height, hand muscle strength), physiological parameters (vital capacity of the lungs (VCL), heart rate (HR)) were determined during the examination. Functional breath-holding tests (the Stange and Hench tests) were performed, the level of physical health was determined by the method of Pyrohova, O.A., the express assessment of the level of somatic health was determined by the method of Apanasenko, H.A., and the method of assessing physical work capacity using the Ruffier test was performed. Descriptive statistics were used for the statistical analysis of the data. The comparison of average values of variable indicators was carried out using parametric methods (Student’s t-test) with the normal distribution of these signs expressed in the interval scale. All calculations were performed in StatSoft Statistica 8.1 for Windows. Results: the data obtained in the course of the research allow us to state that the indicators of the Ruffier index are at “satisfactory” (14,1±0,3) and “average” levels (7,5±1,1). The somatic health indicator was also at the “below average” level in 2018 (4 points), it was at the “average” level (7 points) in 2019, and in 2020 and 2021, this indicator was already at the “above average” level (14 and 13 points, respectively). The level of physical health was also at the “average” level in 2018 (0,560), and in 2021 it was at the “above average” level (0,697). Conclusions: the conducted research showed that the somatic health and physical state of first-year female students of NUPh were improving from year to year (starting from 2018), which is reflected in the health level indicator according to the method of Pyrohova, O.A. and Apanasenko, H.A., the Ruffier index, and the results of the Stange and Hench tests. The Romberg test was within the normal range. The obtained results create broad prospects for their involvement in physical culture and sports activities.